

October 21, 2005

A Petition for a Preliminary Injunction filed by Pfizer about Amlodin

Sumitomo Chemical Company (Sumitomo Chemical) and its subsidiary Dainippon Sumitomo Pharma Co., Ltd. (DSP) have been notified by the attorney of Pfizer (Pfizer Limited and Pfizer Corp. collectively) that Pfizer recently filed a petition at the Tokyo District Court for a preliminary injunction, calling for cessation of manufacture and sale of Amlodin by DSP, etc. Amlodin (Generic name: Amlodipine Besilate) is a therapeutic drug for hypertension and angina pectoris, for which Pfizer is the licensor.

Pfizer's ground for the petition is the same as the one claimed in their earlier petition for a preliminary injunction requesting return to Pfizer of medical data and other information regarding Amlodin, as the Company announced on October 17, 2005.

Sumitomo Chemical and DSP firmly believe, based on the results of thorough studies including those by its external lawyers both in Japan and England, that the legitimacy of the Company's position will be fully affirmed by the Court and that DSP will be able to continue undertaking the Amlodin business with no adverse impact on its earnings.